CHOM . . . Wu Xueling's team selected the broad-spectrum neutralizing antibodies converted into IgG
Time of Update: 2020-07-21
Finally, the team analyzed the epitope recognition of the two broad-spectrum and antibodies on the viral surface membrane protein, and found that both were new.
Express . . . Seek accelerated approval, innovative antibody conjugal drug treatment for cervical cancer Phase 2 clinical results are positive.
Time of Update: 2020-07-18
Seattle Genetics, editor of the ▎'s content team, has announced that it and Genmab have jointly developed an innovative antibody conjugate drug (ADC) tisotumab vedotin, which has obtained positive top-line results in a potentially registered Phase 2
Cervical cancer targeted therapy! Seattle Genetic Antibody Drug Coupling Tisotumab Vedotin Key PHASE II Study Positive Results!
Time of Update: 2020-07-15
currently, tisotumab vedotin is being developed by Seattle Genetics Corporation and Genmab as a monodrug therapy or a combination of other therapies to treat recurrent and/or metastatic cervical and/or metastatic cervical, ovarian and other tumor .
Pfizer/BioNTech New Crown Vaccine Phase 1/2 Results Positive Neutralizing Antibody Levels In Rehab Patients
Time of Update: 2020-07-15
The mRNA vaccine, called BNT162b1, is one of four mRNA vaccines currently being tested by the two companies in clinical trials. Pfizer and BioNTech plan to select the most promising of the four vaccines for large,global 2b/3 clinical trials, which
Novartis CD20 Antibody Treatment Multiple Sclerosis Phase 3 Results Positive
Time of Update: 2020-06-08
The trial consisted of two double-blind, randomized trials, which were a head-to-head comparison trial, comparing the safety and efficacy of the treatment of MS adult patients with teriflunomide.
Asian Lionkang-KY monoclonal antibody ASLAN004 obtains positive results in proof-of-concept test for the treatment of acursions
Time of Update: 2020-06-07
recently, Aslam Pharmaceuticals company ( announced that the company's development of the target IL-13 receptor alpha1 sub-base (IL-13 alpha1) monoclonal antibody ASLAN004, in the treatment of acursion dermatitis test ( positive results.
CAR-T treatment failure patients can also completely mitigate the results of dual-specific antibody clinical trials positive
Time of Update: 2020-06-02
Retrieved June 14, 2019, from
ASH . . . Preliminary clinical results of Roche CD20-CD3 bispecific antibodies positive
Time of Update: 2020-05-31
Lymphoma can be divided into two major categories, Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL), while the NHL has two subtypes that can be classified as invasive and inert. The NHL represents 85% of confirmed cases of lymphoma. According
FDA grants ENHERTU breakthrough therapy for HER2-positive antibody drug conjugated to treat HER2-positive metastatic stomach cancer
Time of Update: 2020-05-29
First Sando co-op and Aslicon's targeted HER2 antibody drug conjugated enHERTU (FAM-trastuzumab deruxtecan-nxki) were awarded the FDA-awarded breakthrough therapy (BTD) for the treatment of patients who have received two or more
ENHERTU, AN ANTIbody drug conjugated with HER2, has been awarded the FDA's breakthrough therapy
Time of Update: 2020-05-29
in December, Enhertu was approved by the FDA for the first time to treat patients who had previously received two or more metastatic HER2-positive breast cancers based on anti-HER2 therapy.
HER2-positive stomach cancer first ADC drug! First three co-antibody drug conjugate (ADC) Enhertu in Japan to submit a new indication sin application!
Time of Update: 2020-05-08
08 May 2020 / Biovalley BIOON / -- Daiichi Sankyo recently announced that it has submitted a new drug supplementary application (ND) to Japan's Ministry of Health, Labour and Welfare (MHLW) A), seek approval of HER2
! The recombinant s-trimer vaccine was successfully expressed by Trifolium repens, and it was confirmed that antibody was positive in many patients!
Time of Update: 2020-02-12
New coronavirus vaccine development! The recombinant s-trimer vaccine was successfully expressed by Trifolium repens, and it was confirmed that antibody was positive in many
Positive clinical results of bispecific antibody precision therapy for specific pancreatic cancer / lung cancer patients
Time of Update: 2019-10-29
Today, merus announced the preliminary clinical results of its bispecific antibody mcla-128 (also known as zenocutuzumab) in the treatment of cancer patients carrying NRG1 gene fusion.
It is expected to treat squamous cell carcinoma of the head and neck. The anti-PD-1 antibody
Time of Update: 2019-10-19
MSD today announced that the European Drug Administration's Committee on human medicinal products (CHMP) recommended approval of two options of keytruda (anti PD-1 therapy of MSD
2019 biomedical trend: investment in targeted drugs and antibody drugs holds the top position
Time of Update: 2019-02-15
For the biological and pharmaceutical industries, 2018 is another extraordinary year
According to the arterial network database, 1410 transactions involving US $38.801
The global position of China's antibody drugs: not only in quantity, but also in innovation!
Time of Update: 2017-12-05
All over the world, biological drugs, especially antibody drugs, have begun to break out their vitality after years of basic research and technology accumulation, and become
Roche's $490 million acquisition of dual specific antibody platform dutamab to consolidate the leading position in therapeutic antibody field
Time of Update: 2014-12-19
Through the acquisition of dutalys, Roche obtained the platform dutamab, which will provide novel bispecific antibody drugs for multiple therapeutic fields.